Chris Cooley
Stock Analyst at Stephens & Co.
(3.09)
# 1,111
Out of 5,182 analysts
55
Total ratings
71.05%
Success rate
44.18%
Average return
Main Sectors:
Stocks Rated by Chris Cooley
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VCEL Vericel | Maintains: Overweight | $39 → $42 | $35.68 | +17.71% | 2 | May 11, 2023 | |
| ALGN Align Technology | Maintains: Overweight | $500 → $375 | $190.07 | +97.30% | 7 | Jul 28, 2022 | |
| COO The Cooper Companies | Maintains: Overweight | $125 → $115 | $70.06 | +64.15% | 9 | Jun 3, 2022 | |
| ALC Alcon | Upgrades: Overweight | $86 → $92 | $81.32 | +13.13% | 4 | May 12, 2022 | |
| PLSE Pulse Biosciences | Maintains: Overweight | $14 → $12 | $23.40 | -48.72% | 2 | Apr 1, 2022 | |
| ANIK Anika Therapeutics | Downgrades: Equal-Weight | n/a | $16.00 | - | 2 | Mar 9, 2022 | |
| ESTA Establishment Labs Holdings | Maintains: Overweight | $88 → $90 | $67.08 | +34.17% | 3 | Nov 10, 2021 | |
| STE STERIS | Maintains: Overweight | $255 → $270 | $225.79 | +19.58% | 5 | Nov 4, 2021 | |
| GKOS Glaukos | Upgrades: Overweight | $60 → $68 | $124.79 | -45.51% | 5 | Nov 3, 2021 | |
| AVNS Avanos Medical | Downgrades: Equal-Weight | $60 → $45 | $24.62 | +82.78% | 2 | Aug 4, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $425 → $275 | $131.58 | +109.00% | 5 | Mar 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $56 → $37 | $25.08 | +47.53% | 2 | Mar 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $75 → $60 | $63.98 | -6.22% | 3 | Mar 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $48 → $35 | $64.23 | -45.51% | 2 | Mar 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $60 → $81 | $203.73 | -60.24% | 2 | Feb 22, 2018 |
Vericel
May 11, 2023
Maintains: Overweight
Price Target: $39 → $42
Current: $35.68
Upside: +17.71%
Align Technology
Jul 28, 2022
Maintains: Overweight
Price Target: $500 → $375
Current: $190.07
Upside: +97.30%
The Cooper Companies
Jun 3, 2022
Maintains: Overweight
Price Target: $125 → $115
Current: $70.06
Upside: +64.15%
Alcon
May 12, 2022
Upgrades: Overweight
Price Target: $86 → $92
Current: $81.32
Upside: +13.13%
Pulse Biosciences
Apr 1, 2022
Maintains: Overweight
Price Target: $14 → $12
Current: $23.40
Upside: -48.72%
Anika Therapeutics
Mar 9, 2022
Downgrades: Equal-Weight
Price Target: n/a
Current: $16.00
Upside: -
Establishment Labs Holdings
Nov 10, 2021
Maintains: Overweight
Price Target: $88 → $90
Current: $67.08
Upside: +34.17%
STERIS
Nov 4, 2021
Maintains: Overweight
Price Target: $255 → $270
Current: $225.79
Upside: +19.58%
Glaukos
Nov 3, 2021
Upgrades: Overweight
Price Target: $60 → $68
Current: $124.79
Upside: -45.51%
Avanos Medical
Aug 4, 2021
Downgrades: Equal-Weight
Price Target: $60 → $45
Current: $24.62
Upside: +82.78%
Mar 23, 2020
Maintains: Overweight
Price Target: $425 → $275
Current: $131.58
Upside: +109.00%
Mar 23, 2020
Maintains: Overweight
Price Target: $56 → $37
Current: $25.08
Upside: +47.53%
Mar 23, 2020
Maintains: Overweight
Price Target: $75 → $60
Current: $63.98
Upside: -6.22%
Mar 23, 2020
Maintains: Overweight
Price Target: $48 → $35
Current: $64.23
Upside: -45.51%
Feb 22, 2018
Maintains: Equal-Weight
Price Target: $60 → $81
Current: $203.73
Upside: -60.24%